Form 4: Nuvalent CEO Exercises Options and Sells Shares Under 10b5-1 Plan

Nuvalent's CEO, James Richard Porter, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Summary

• Nuvalent's CEO, James Richard Porter, executed transactions involving the company's Class A Common Stock on December 16, 2024.
• Mr. Porter exercised stock options to acquire 27,000 shares at a price of $27.85 per share.
• He then sold 18,969 shares at a weighted average price of $86.46 and 8,031 shares at a weighted average price of $86.96.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on April 2, 2024.
• Following these transactions, Mr. Porter directly owns 188,113 shares of Class A Common Stock and 339,780 stock options.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions under a pre-arranged plan, which is neither particularly positive nor negative.

Risks

• The CEO's sale of shares, even under a pre-arranged plan, could be perceived negatively by some investors.

Industry Context

This is a routine filing for insider transactions and is common for executives who have stock options and use 10b5-1 plans to manage their holdings.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
• The vesting schedule of the stock options is typical for executive compensation packages in the biotech industry.
• The sale of shares after exercising options is a standard practice for executives to realize gains from their equity compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, but are unlikely to significantly affect the company's operations or financial position.

Key Dates

Keywords

Form 4, Insider Trading, Stock Options, Rule 10b5-1, Share Sale, Nuvalent, NUVL, Executive Compensation